SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFC14A - Definitive proxy statement, contested solicitations:
SEC Accession No. 0000921895-18-000230
Filing Date
2018-01-23
Accepted
2018-01-22 18:32:23
Documents
3
Effectiveness Date
2018-01-23

Document Format Files

Seq Description Document Type Size
1 defc14a09271023_01222018.htm DEFC14A 218081
2 GRAPHIC image_logo.jpg GRAPHIC 9306
3 GRAPHIC image_chart.jpg GRAPHIC 88732
  Complete submission text file 0000921895-18-000230.txt   355303
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Subject) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: DEFC14A | Act: 34 | File No.: 001-35285 | Film No.: 18540768
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 13100 GREGG STREET SUITE A POWAY CA 92064
Business Address 1048 INDUSTRIAL COURT SUWANEE GA 30024 (858) 726-1600
DIGIRAD CORP (Filed by) CIK: 0000707388 (see all company filings)

IRS No.: 330145723 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFC14A
SIC: 3845 Electromedical & Electrotherapeutic Apparatus